Frassica Michael, Kern Drew S, Afshari Mitra, Connolly Allison T, Wu Chengyuan, Rowland Nathan, Ramirez-Castaneda Juan, Ushe Mwiza, Salazar Claudia, Mason Xenos
Abbott Laboratories, Austin, TX, United States.
Department of Neurology, University of Colorado School of Medicine, Aurora, CO, United States.
Front Neurol. 2023 Aug 1;14:1233684. doi: 10.3389/fneur.2023.1233684. eCollection 2023.
Deep brain stimulation (DBS) is an effective and standard-of-care therapy for Parkinson's Disease and other movement disorders when symptoms are inadequately controlled with conventional medications. It requires expert care for patient selection, surgical targeting, and therapy titration. Despite the known benefits, racial/ethnic disparities in access have been reported. Technological advancements with smartphone-enabled devices may influence racial disparities. Real-world evidence investigations can shed further light on barriers to access and demographic disparities for DBS patients.
A retrospective cross-sectional study was performed using Medicare claims linked with manufacturer patient data tracking to analyze 3,869 patients who received DBS. Patients were divided into two categories: traditional omnidirectional DBS systems with dedicated proprietary controllers ("traditional"; = 3,256) and directional DBS systems with smart controllers ("smartphone-enabled"; = 613). Demographics including age, sex, and self-identified race/ethnicity were compared. Categorical demographics, including race/ethnicity and distance from implanting facility, were analyzed for the entire population.
A significant disparity in DBS utilization was evident. White individuals comprised 91.4 and 89.9% of traditional and smartphone-enabled DBS groups, respectively. Non-White patients were significantly more likely to live closer to implanting facilities compared with White patients.
There is great racial disparity in utilization of DBS therapy. Smartphone-enabled systems did not significantly impact racial disparities in receiving DBS. Minoritized patients were more likely to live closer to their implanting facility than White patients. Further research is warranted to identify barriers to access for minoritized patients to receive DBS. Technological advancements should consider the racial discrepancy of DBS utilization in future developments.
当帕金森病和其他运动障碍的症状无法通过传统药物得到充分控制时,深部脑刺激(DBS)是一种有效且符合护理标准的治疗方法。它需要专家进行患者选择、手术靶点定位和治疗滴定。尽管已知其益处,但已有报道称在获得治疗方面存在种族/族裔差异。智能手机设备的技术进步可能会影响种族差异。真实世界证据调查可以进一步揭示DBS患者获得治疗的障碍和人口统计学差异。
进行了一项回顾性横断面研究,使用与制造商患者数据跟踪相关联的医疗保险索赔数据,分析了3869例接受DBS治疗的患者。患者分为两类:使用专用专有控制器的传统全向DBS系统(“传统型”;n = 3256)和使用智能控制器的定向DBS系统(“支持智能手机型”;n = 613)。比较了包括年龄、性别和自我认定的种族/族裔在内的人口统计学特征。对整个人口分析了包括种族/族裔和与植入机构的距离在内的分类人口统计学特征。
DBS使用情况存在显著差异。白人分别占传统DBS组和支持智能手机型DBS组的91.4%和89.9%。与白人患者相比,非白人患者居住得离植入机构更近的可能性显著更高。
DBS治疗的使用存在很大的种族差异。支持智能手机的系统并未显著影响接受DBS治疗的种族差异。少数族裔患者比白人患者更有可能居住在离其植入机构更近的地方。有必要进行进一步研究,以确定少数族裔患者接受DBS治疗的障碍。技术进步在未来发展中应考虑DBS使用的种族差异。